Loading…
Contineum Therapeutics, Inc. is projected to rise to $14.57 by 2027, a +8% move from its current price of $13.44. CTNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.02 | $13.44 | $13.87 | -0.03% |
| May 30 | $12.84 | $13.43 | $14.05 | -0.05% |
| May 31 | $12.71 | $13.43 | $14.19 | -0.08% |
| Jun 1 | $12.60 | $13.43 | $14.30 | -0.11% |
| Jun 2 | $12.50 | $13.42 | $14.41 | -0.13% |
| Jun 3 | $12.42 | $13.42 | $14.50 | -0.16% |
| Jun 4 | $12.34 | $13.42 | $14.59 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.34 | $13.42 | $14.59 | -0.18% |
| Week 2 | $11.89 | $13.39 | $15.07 | -0.37% |
| Week 3 | $11.56 | $13.37 | $15.45 | -0.55% |
| Week 4 | $11.28 | $13.34 | $15.77 | -0.74% |
| Week 5 | $11.04 | $13.32 | $16.06 | -0.92% |
| Week 6 | $10.83 | $13.29 | $16.32 | -1.10% |
| Week 7 | $10.63 | $13.27 | $16.56 | -1.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Contineum Therapeutics, Inc. is a healthcare company focused on developing small-molecule therapies for neuroscience, inflammation, and immunology indications in the United States. The company is based in San Diego, California, and was incorporated in 2009.
It was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
The lead asset is PIPE-791, a novel brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. The company also develops PIPE-307, a novel small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
These programs position Contineum as a clinical-stage biopharmaceutical company pursuing therapies across neuroscience, inflammation, and immunology indications in the United States.
CTNM is trading at $13.86 with a market capitalization of $518.18M and ranks 3017 by market cap. The stock’s current price and market position place it among mid-cap healthcare equities.
Near-term dynamics show a neutral-to-bullish setup on the chart, while the longer-term forecast points to meaningful upside over the next several years. The multi-year price outlook includes rising average targets and substantially higher potential returns, starting from a baseline near the current price and expanding toward the 2030–2050 horizon.
A major floor 21.3% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 11.2% above — a clean break opens room to run.
A major ceiling 21.8% above — clearing it would confirm fresh momentum.
Key CTNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.75 | Sell | $13.63 | Sell |
| MA 10 | $13.65 | Sell | $13.66 | Sell |
| MA 20 | $13.72 | Sell | $13.61 | Sell |
| MA 50 | $13.24 | Buy | $13.48 | Sell |
| MA 100 | $13.40 | Buy | $13.10 | Buy |
| MA 200 | $12.24 | Buy | $12.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.79 | Neutral |
| Stoch RSI (14) | 31.50 | Neutral |
| CCI (20) | -33.05 | Neutral |
| Williams %R (14) | -63.64 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -7.50 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 36.36 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 0.34 | Buy |
| Ultimate (7,14,28) | 44.13 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 13.91 | Sell |
| ADX (14) | 10.04 | Neutral |
| ATR (14) | 0.42 | Info |
The 30-day technical picture is labeled BULLISH with RSI14 at 50. The stock trades above the SMA50 at $13.23 and above the SMA200 at $12.17, suggesting a positive short-term momentum.
Support sits at $12.04 and resistance at $14.94, framing a constructive range near the current level. The 30-day range spans from $11.12 to $17.27, and annualized volatility is 60%, indicating notable swings but with an overall bullish tilt.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.17 | $13.44 | $17.29 | 0% | Neutral | |
| $11.38 | $14.57 | $19.87 | +8% | Neutral | |
| $11.70 | $15.47 | $21.97 | +15% | Neutral | |
| $11.81 | $16.04 | $23.52 | +19% | Neutral | |
| $14.99 | $20.86 | $31.42 | +55% | Bullish | |
| $17.60 | $25.03 | $38.59 | +86% | Bullish | |
| $18.00 | $26.13 | $41.14 | +94% | Bullish | |
| $18.21 | $26.96 | $43.27 | +101% | Bullish | |
| $18.42 | $27.78 | $45.37 | +107% | Bullish | |
| $19.75 | $30.33 | $50.34 | +126% | Bullish | |
| $27.40 | $45.65 | $81.09 | +240% | Bullish | |
| $52.29 | $100.59 | $197.18 | +648% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.17 | $13.44 | $15.74 | +0.00% |
| June 2026 | $11.01 | $12.98 | $15.69 | -3.44% |
| July 2026 | $11.02 | $13.12 | $16.11 | +1.09% |
| August 2026 | $10.96 | $13.14 | $16.33 | +0.16% |
| September 2026 | $10.52 | $12.70 | $15.94 | -3.35% |
| October 2026 | $10.49 | $12.74 | $16.12 | +0.28% |
| November 2026 | $10.92 | $13.32 | $16.99 | +4.59% |
| December 2026 | $10.98 | $13.46 | $17.29 | +1.06% |
Click any year to see its month-by-month CTNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Contineum Therapeutics, Inc.'s 2026 outlook centres on $13.44, within a $9.17 to $17.29 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTNM could reach as high as $19.87, with a base case around $14.57 and support toward $11.38 — roughly +8% from $13.44. Price action looks broadly range-bound.
Expect CTNM to range from $11.70 to $21.97 through 2028. The $15.47 average target implies a +15% move from current prices. That is up +6% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CTNM price prediction for 2029 points to an average of $16.04 (low $11.81, high $23.52) — a potential gain of +19% on today's $13.44. Price action looks broadly range-bound.
In 2030, CTNM is projected to trade between $14.99 and $31.42, averaging $20.86 — a potential gain of +55% from today's $13.44. That is up +30% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Contineum Therapeutics, Inc.'s 2031 outlook centres on $25.03, within a $17.60 to $38.59 range. That is up +20% on the projected 2030 average. That marks a +86% change versus current levels. Momentum favours further upside here.
By 2032, CTNM could reach as high as $41.14, with a base case around $26.13 and support toward $18.00 — roughly +94% from $13.44. Buyers look set to stay in control over this stretch.
Expect CTNM to range from $18.21 to $43.27 through 2033. The $26.96 average target implies a +101% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The CTNM price prediction for 2034 points to an average of $27.78 (low $18.42, high $45.37) — a potential gain of +107% on today's $13.44. Buyers look set to stay in control over this stretch.
In 2035, CTNM is projected to trade between $19.75 and $50.34, averaging $30.33 — a potential gain of +126% from today's $13.44. That is up +9% on the projected 2034 average. Momentum favours further upside here.
Contineum Therapeutics, Inc.'s 2040 outlook centres on $45.65, within a $27.40 to $81.09 range. That is up +51% on the projected 2035 average. That marks a +240% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTNM could reach as high as $197.18, with a base case around $100.59 and support toward $52.29 — roughly +648% from $13.44. Momentum favours further upside here.
Investing $1,000 in CTNM today (≈ 74.404762 CTNM) could be worth
$7,484.17
+$6,484.17 (+648%) by 2050 · US Dollar
Based on the average projected CTNM price of $100.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTNMwould be worth at today's price.
$1,000 invested in CTNM on May 27, 2025 (≈ 285.306695 CTNM) would be worth
$3,834.52
+$2,834.52 (+283.5%) today · 3.83× · US Dollar
Based on a CTNM entry price of $3.51 vs. today's $13.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.39 | $1,003.73 | +0.4% |
| 1 month ago | $12.97 | $1,036.24 | +3.6% |
| 3 months ago | $15.78 | $851.71 | -14.8% |
| 6 months ago | $11.07 | $1,214.09 | +21.4% |
| 1 year ago | $3.51 | $3,834.52 | +283.5% |
| All time (2.1y) ago | $15.4 | $872.73 | -12.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTNM forecast.
Our base-case forecast reaches $27.00 around 2034.
Implied market cap at $27.00: $883.54M
The multi-year forecast shows significant upside beyond the near term. In 2030, the average target is $23.70 with a minimum of $16.83 and a maximum of $36.14, corresponding to an ROI of 71% and a bullish sentiment for that horizon.
By 2040, the average target rises to $54.81 (min $32.09, max $99.21) with an ROI of 295.4% and a bullish sentiment, signaling substantial long-term appreciation potential.
In 2050, the average target reaches $125.47 (min $62.84, max $251.42) with an ROI of 805.3% and a bullish sentiment, reflecting the strongest long-term outlook in the provided forecast.
These forward targets imply a gradual to accelerated upside over time, though they are estimates and not guarantees. The asset’s status as a clinical-stage program with lead and supportive assets under development underpins the risk and potential for outsized long-run moves.
Tap a question to reveal the answer.
2030 forecast: min $16.83, avg $23.70, max $36.14; ROI 71%; sentiment BULLISH.
Long-term forecasts show rising prices with average targets: 2030 $23.70, 2040 $54.81, 2050 $125.47 and ROI up to 805.3%, with bullish sentiment in the later years. These are estimates, not guarantees.
Yes. The 2030 forecast lists a max of $36.14 with an average of $23.70 and a min of $16.83.
2040 forecast: min $32.09, avg $54.81, max $99.21; ROI 295.4%, sentiment BULLISH.
2050 forecast: min $62.84, avg $125.47, max $251.42; ROI 805.3%, sentiment BULLISH.
Contineum Therapeutics, Inc. Community Discussion
0Share your Contineum Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.